Hangzhou Tigermed Consulting Co., Ltd. Class A · SZSE:300347
Hangzhou Tigermed Consulting Co., Ltd. Class A — J.P. Morgan Healthcare Conference 2024
20 slides from Hangzhou Tigermed Consulting Co., Ltd. Class A's conference presentation, January 2024
Slide 1: J.P. Morgan Healthcare Conference 2024
J.P. Morgan Healthcare Conference 2024 Hangzhou Tigermed Consulting Co., Ltd. 300347.SZ / 3347.HK San Francisco, CA, US January 2024 www.tigermedgrp.com
Slide 2: Disclaimer
Disclaimer By reading these materials, you agree to be bound by the following limitations: The information herein has been prepared by representatives of Hangzhou Tigermed Consulting Co., Ltd. (杭州泰格医药科技股份有限公司, the “Company”) solely for your information and have not been independently verified. The i
Slide 3: What have We Seen in an Eventful 2023?
What have We Seen in an Eventful 2023? 100% A record-high 48 Class-1 A booming out-licensing ICH guidelines implementation innovative drugs approved partnerships with a total in China by 2023(1) in 2023(2) size of $41+ Billion(3) Full harmonization of regulatory regime 44 of them were launched by Ch
Slide 4: China Innovative Drug Assets Start to Display a Different Pattern
China Innovative Drug Assets Start to Display a Different Pattern… China-originated assets started to pursue differentiated innovation and global-competitive modality Stage 1 Stage 2 Stage 3 Catching Up A Closer Gap Global Recognition 2010-2017 2017-2021 2021 onwards • Majority of pipeline are pure
Slide 5: And Start to Show Impact on Global Stage
…And Start to Show Impact on Global Stage… “In China For China” story no longer the only priority 31 37 27 # of innovative drug out-licensing 16 19 7 2 and EU5 deals(1) from China to US as % of global out-licensing deals 3% 4% 6% 7% 13% FDA Breakthrough Therapy 3 Designation granted to 2 2 2 China-o
Slide 6: With Recognition by Global Market Leaders
…With Recognition by Global Market Leaders In 2023, transactions involving China innovative drug assets continued to heat up and hit a record high, reflecting a greater influence in the global biopharma industry and a higher recognition from global market leaders A record-breaking out- The first lis
Slide 7: Select US$1Bn+ Out-Licensing Deals from China Biopharma in 2023
Select US$1Bn+ Out-Licensing Deals from China Biopharma in 2023 Mostly focus on advanced therapies (e.g. ADC and CGT, etc.) Date Licensor Licensee Asset Type Upfront Total Potential Size (US$ in millions) (US$ in millions) January HutchMed Takeda Fruquintinib Chemical 400 1,130 February Keymed and L
Slide 8: Funding Environment and Sentiment Remains Weak
Funding Environment and Sentiment Remains Weak Divergence of the trend between PE/VC investment and out-licensing transactions 41.1 PE/VC Fund Investment to China Biopharma(1) US$ in billions 26.8 Upfront Payment to China Biopharma from Out- Licensing Deals(2) Potential Total Size from Out-Licensing
Slide 9: Potential Future Trends for China-based Innovative Drug Assets
Potential Future Trends for China-based Innovative Drug Assets “Made for China and made from China” From Biopharma/Big Pharma From Biotech/Start-up Fast following with speed and Fast follow for local commercialization differentiation after clinical validation in developed markets Clinical Value-Orie
Slide 10: Sales of Domestic Innovative Drugs in China Continued to Ramp up in 2023
Sales of Domestic Innovative Drugs in China Continued to Ramp up in 2023 Top China innovative drugs approved between 2018-2022 Historical sales of select domestic innovative drugs in by domestic sales in 3Q2023 China(1) (2018-3Q2023) RMB in millions Company Product Target 18,000 BeiGene Tislelizumab
Slide 11: Regulatory Environment Further Enhanced for Clinical Development
Regulatory Environment Further Enhanced for Clinical Development Select key regulations by NMPA and related authorities in 2023 Protecting patients’ rights regarding Promoting patient-centric practice in ethical management clinical research “Regulations to ethical review of biomedical life “Guidelin
Slide 12: Clinical Development Pipeline and Resources are Growing in China
Clinical Development Pipeline and Resources are Growing in China Clinical trial activities remain strong and the number of clinical trials in China tops the world for three-consecutive years Newly started innovative drug clinical trials in Number of certified clinical trial sites Total number of all
Slide 13: China Sites Play a Bigger Role in Global Clinical Trials
China Sites Play a Bigger Role in Global Clinical Trials Global clinical trials by 3,000 destination country/region 2,500 China 2018-2023 2,000 US 1,500 1,000 Europe Japan 500 Korea Latin America SEA 2018 2019 2020 2021 2022 2023 Africa % of China site involvement in global clinical trials 6.2% 6.4%
Slide 14: Chinese Companies are Pursuing Clinical Trials Globally
Chinese Companies are Pursuing Clinical Trials Globally Clinical trials initiated by Chinese companies Clinical trials initiated by Chinese companies Building global clinical capabilities in overseas countries(1) (2018-2023) in overseas countries by country/region(2) with local team and more oversea
Slide 15: Real World Evidence to Play an Increasingly Important Role in China
Real World Evidence to Play an Increasingly Important Role in China Real World Evidence (RWE) to play a growing role to secure registration and become a new pathway to access vast Chinese market Regulatory Support Unique opportunity Success Story Guidelines and technical principles have Using RWE to
Slide 16: Embracing Decentralized Clinical Trials (DCTs) – Swift and Bold
Embracing Decentralized Clinical Trials (DCTs) – Swift and Bold Decentralized clinical trials are becoming an increasingly important part of the clinical research landscape in China Regulatory Support Patient Acceptance Ecosystem is forging Intensive regulations on encouraging DCT Acceptance of over
Slide 17: Tigermed: Leader and Key Enabler of China Innovative Drug Research
Tigermed: Leader and Key Enabler of China Innovative Drug Research 92 The Leading Clinical Research Service Provider in China China Innovative in both Scale and Market Share Drugs We Served Provided services to the development of 92 approved Tigermed has the largest market Leveraging unique global l
Slide 18: Tigermed: End-to-End Service Offerings from Lab to Clinical
Tigermed: End-to-End Service Offerings from Lab to Clinical Drug Preclinical Investigational Phase I-III Clinical NDA & BLA Post Market / Discovery Development New Drug Development Registration RWS Molecular Design PD Study Clinical Development Post-market Research Medicinal Chemistry Safety & Tox (
Slide 19: Tigermed: Strategically Located with Global Operation and Local Expertise
Tigermed: Strategically Located with Global Operation and Local Expertise North America Team: 850+ • Laboratory facilities in 8 cities across North America • Partnering with over 100 sites across 33 States in US • Local expertise in clinical monitoring / PM / biometrics / regulatory, etc. China Team
Slide 20: Hangzhou Tigermed Consulting Co., Ltd.
Hangzhou Tigermed Consulting Co., Ltd. 300347.SZ / 3347.HK Global Headquarters 18/F, Building A, Shengda Science Park, 19 Jugong Road, Binjiang District, Hangzhou, People’s Republic of China International Headquarters 1201, Harbour East, 218 Electric Rd, North Point, Hong Kong SAR www.tigermedgrp.co
Hangzhou Tigermed Consulting — J.P. Morgan Healthcare Conference 2024 on 6ix